Robert Wenham, MD, MS, FACS, On Assessing FSHR-CAR-T Therapy in Ovarian Cancer


The chair of gynecologic oncology at Moffitt Cancer Center gave an overview of a phase 1 trial being conducted at Moffitt Cancer Center.

“This is somewhat unique in that we're delivering the cells directly into the peritoneal cavity... We don't really know if intraperitoneal is necessary. There's lots of reasons you could theorize while intraperitoneal may be good, because that's where most of theovarian cancer is... There is also some preclinical data suggesting that that may be the preferred route as well, and we will find out.”

A phase 1 study (NCT05316129) being conducted at Moffitt Cancer Center, in Tampa, Florida, is evaluating Anixa Biosciences’ chimeric endocrine receptor T-cell (CER-T) therapy targeting follicle stimulating hormone receptor (FSHR) for the potential treatment of ovarian cancer.

The dose-escalation study will determine the maximum tolerated dose of the CER-T therapy and will evaluate its safety profile in up to 48 participants delivered either intravenously or through intraperitoneal injection. The first patient with ovarian cancer was dosed in August 2022.

CGTLive spoke with the trial’s principal investigator Robert Wenham, MD, MS, FACS. Wenham serves as the chair of gynecologic oncology at Moffitt Cancer Center.Wenham discussed enrollment, protocols, and outcomes of the trial. He stressed the interdisciplinary collaboration available at Moffitt aswell as the value of his colleagues’ previous experiences and research.

Anixa Biosciences announces treatment of first patient in its ovarian cancer CAR-T clinical trial. News release. August 15, 2022.
Related Videos
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up
Omid Hamid, MD, on Clinic Experience With TIL vs CAR-T Therapy Administration
N. Nora Bennani, MD, on Diving Deeper Into T-Cell Lymphomas
Xandra Breakefield, PhD, on Trying New Approaches to AAV Therapy for Glioblastoma
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
© 2024 MJH Life Sciences

All rights reserved.